Vertex Pharmaceuticals Incorporated $VRTX Stake Increased by Leeward Financial Partners LLC

Leeward Financial Partners LLC increased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 8.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 716 shares of the pharmaceutical company’s stock after buying an additional 58 shares during the period. Leeward Financial Partners LLC’s holdings in Vertex Pharmaceuticals were worth $319,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Activest Wealth Management bought a new stake in shares of Vertex Pharmaceuticals in the first quarter worth $25,000. Clal Insurance Enterprises Holdings Ltd lifted its stake in Vertex Pharmaceuticals by 450.0% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 45 shares during the last quarter. Flaharty Asset Management LLC bought a new position in Vertex Pharmaceuticals during the first quarter worth $32,000. American National Bank & Trust lifted its stake in Vertex Pharmaceuticals by 515.4% during the second quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company’s stock worth $36,000 after purchasing an additional 67 shares during the last quarter. Finally, Solstein Capital LLC bought a new position in Vertex Pharmaceuticals during the second quarter worth $40,000. Institutional investors own 90.96% of the company’s stock.

Analyst Upgrades and Downgrades

VRTX has been the topic of several research analyst reports. Truist Financial set a $490.00 price objective on Vertex Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 5th. Morgan Stanley reduced their price objective on Vertex Pharmaceuticals from $439.00 to $438.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. Wells Fargo & Company upgraded Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $460.00 price objective on the stock in a research note on Wednesday, August 6th. Weiss Ratings restated a “hold (c+)” rating on shares of Vertex Pharmaceuticals in a research note on Wednesday, October 8th. Finally, BMO Capital Markets set a $530.00 price objective on Vertex Pharmaceuticals and gave the stock an “outperform” rating in a research note on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and twelve have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $492.10.

Insider Activity at Vertex Pharmaceuticals

In other news, Director Bruce I. Sachs bought 5,000 shares of the stock in a transaction that occurred on Wednesday, August 6th. The shares were purchased at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the acquisition, the director directly owned 45,000 shares in the company, valued at approximately $17,535,600. The trade was a 12.50% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX opened at $425.57 on Friday. The firm has a market capitalization of $109.11 billion, a price-to-earnings ratio of 30.42 and a beta of 0.43. Vertex Pharmaceuticals Incorporated has a one year low of $362.50 and a one year high of $519.88. The stock’s fifty day moving average is $401.71 and its 200-day moving average is $432.43.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. The company had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The company’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same period last year, the company earned ($12.83) earnings per share. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.